We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
268 result(s) found, displaying 61 to 70
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INVEGA HAFYERA paliperidone (as palmitate) 700 mg in 3.5 mL modified release suspension for injection pre-filled syringe.
-
-
Prescription medicine decision summaryTGA decision: Rybrevant (amivantamab) is approved to treat lung cancer
-
Designation or determinationProvisional determination
-
Prescription medicine registrationActive ingredients: amivantamab.
-
Australian public assessment report (AusPar)For the treatment of adult patients with relapsing forms of multiple sclerosis
-
Australian public assessment report (AusPar)AusPAR for DARZALEX SC (daratumumab) for the treatment of light chain AL amyloidosis
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPRAVATO esketamine (as hydrochloride) 28 mg per 2 actuations nasal spray solution.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DARZALEX SC daratumumab 1800 mg/15 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for IMBRUVICA ibrutinib 280 mg film-coated tablet blister.